Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that rec⦠read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
$0.90
Price+0.48%
$0.01
$9.684m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$5.388m
-
1y CAGR-
3y CAGR-
5y CAGR-$14.608m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.37
-
1y CAGR-
3y CAGR-
5y CAGR$10.490m
$14.768m
Assets$4.277m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$10.884m
-
1y CAGR-
3y CAGR-
5y CAGR